Xspray Pharma has received approval for a patent in the United States. The patent covers the composition relating to the product candidate, HyNap-Dasa. It is Xspray’s first product patent approval in the US and it covers the US main market. The company has previously received patent approval in Japan and has additional ongoing applications for corresponding patents in the US, Japan and Europe.
“We now have a patent granted on our most important market thus confirming our innovative work and improving our forthcoming negotiating position with potential partners,” Says Per Andersson, CEO of Xspray Pharma.
Xspray Pharma has received a “Notice of allowance” for a patent in the United States regarding the HyNap-Dasa product candidate intended for the treatment of certain cancers. It is the first product-related patent granted for the company’s product candidate in the most important market, USA. The message is in accordance with the company’s plan to apply for and obtain patents for the composition and methodology of all three product candidates under development in the three most important markets, USA, Europe and Japan.
“We are focusing on launching our product candidates primarily in the US market. A well-functioning patent strategy fills an important function and gaining this approval supports our goal of creating a strong patent portfolio,” further commented Xsprey’s CEO, Per Andersson.
Xspray Pharma’s shares were introduced on September 28th on Nasdaq First North Growth Market after a successful new issue which led the company to SEK 132 million before issue costs. The plan is now to use the capital to develop three product candidates and prospective cancer drugs based on the company’s proprietary technology, and to introduce the first products on the US market in the 2020-2023 period.
For further information, please contact:
Per Andersson, CEO, Xspray Pharma AB (publ)
Mobile: +46 (0)706 88 23 48
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. Xspray uses its innovative and patented RightSize-technology in order to develop improved, as well as generic, versions of already marketed cancer drugs, mainly protein kinase inhibitors (PKI), in the treatment of cancer. The segment is the second largest within the oncology department and the drug prices are very high. Through the company’s innovative technology, Xspray can enter the market as a primary competitor to the current original drugs without interference from secondary patents. Xspray’s goal is to have three products ready for launch during the period 2020-2023, with a first product launch by 2021 at the latest. The Company has patents on production technology, equipment as well as on the resulting products. Xspray’s Certified Adviser is Redeye AB, www.redeye.se.
Xspray Pharma AB (publ)
Gunnar Asplunds Allé 326
171 63 Solna